Thomas W Laver

16PUBLICATIONS
33CO-AUTHORS
Epigenetics (incl. genome methylation and epigenomics)Molecular evolutionMedical mycologyGene mappingGene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (16)

|Mar 31, 2026
Long-read sequencing enables trio-assisted phasing of <i>de novo</i> variants in the imprinted gene <i>MAGEL2</i>.

Thomas W Laver, Preeah Sangha, Lucy Mallin

|Nov 25, 2025
MODY Is Prevalent in Later-Onset Diabetes and Has Potential for Targeted Therapy but Is Challenging to Identify.

Luke N Sharp, Uyenlinh L Mirshahi, Kevin Colclough

|Nov 01, 2025
Population Prevalence, Penetrance, and Mortality for Genetically Confirmed MODY.

Luke N Sharp, Kevin Colclough, Jacques Murray Leech

|Aug 08, 2025
Rare Variants in NEUROD1 and PDX1 Are Low-Penetrance Causes of MODY, Whereas Those in APPL1 and WFS1 Are Not Associated With MODY.

Aparajita Sriram, Matthew N Wakeling, Andrew T Hattersley

|Apr 14, 2025
REVEL Is Better at Predicting Pathogenicity of Loss-of-Function than Gain-of-Function Variants.

Jasmin J Hopkins, Matthew N Wakeling, Matthew B Johnson

|Apr 11, 2024
Chromosome 20p11.2 deletions cause congenital hyperinsulinism via the loss of FOXA2 or its regulatory elements.

Thomas W Laver, Matthew N Wakeling, Richard C Caswell

Pageof 3

Frequent Collaborators

8 joint publications

Kashyap A Patel

7 joint publications

Sarah E Flanagan

6 joint publications

Andrew T Hattersley

6 joint publications

Matthew N Wakeling